<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Mylan Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/mylan-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MYL) Mylan&#8217;s Portfolio Strengthens</title>
		<link>http://www.stockbloghub.com/2009/08/28/myl-mylans-portfolio-strengthens/13810</link>
		<comments>http://www.stockbloghub.com/2009/08/28/myl-mylans-portfolio-strengthens/13810#comments</comments>
		<pubDate>Fri, 28 Aug 2009 23:56:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Incorporated]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13810</guid>
		<description><![CDATA[We are pleased to hear that Mylan (MYL) has begun to market the generic version of BenzaClin (1% Clindamycin and 5% Benzoyl Peroxide Gel) for acne treatment, which was originally manufactured by Sanofi-Aventis (SNY). The drug has been developed under an agreement between its subsidiary, Mylan Pharmaceuticals and Dow Pharmaceutical Sciences, a subsidiary of Valeant Pharmaceuticals International. Earlier this month, Dow received the US Food and Drug Administration (FDA) approval for the generic drug. Although the approval is good news for the company, we do not expect it to contribute significantly to the top line since BenzaClin had total U.S. sales of about $221 million for the 12 months ending June 30 (as per IMS data). This is the third approval for Mylan in the month of August. A few ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/28/myl-mylans-portfolio-strengthens/13810/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck received a favorable ruling in a major patent-infringement suit</title>
		<link>http://www.stockbloghub.com/2009/08/20/mrk-merck-received-a-favorable-ruling-in-a-major-patent-infringement-suit/12906</link>
		<comments>http://www.stockbloghub.com/2009/08/20/mrk-merck-received-a-favorable-ruling-in-a-major-patent-infringement-suit/12906#comments</comments>
		<pubDate>Thu, 20 Aug 2009 19:00:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12906</guid>
		<description><![CDATA[Merck (MRK) received a favorable ruling in a major patent-infringement suit yesterday against the largest generic player, Teva Pharmaceuticals (TEVA), on its top-selling drug Singulair. Teva was seeking the Food and Drug Administration’s (FDA) approval for selling a generic version of the drug for asthma and allergic rhinitis. The litigation has been continuing since Merck sued Teva in February 2007. During the second quarter of 2009, Singulair recorded worldwide sales of $1.3 billion, up 16% from the year-ago period. The drug had total sales of $4.3 billion in fiscal 2008, accounting for about 18% of Merck’s total revenue. Defending Singulair’s patent was thus quite crucial for Merck. We believe this is a major win for Merck as an unfavorable ruling would have hurt its top-line badly. The court not only ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/20/mrk-merck-received-a-favorable-ruling-in-a-major-patent-infringement-suit/12906/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Drug Gets Tentative OK</title>
		<link>http://www.stockbloghub.com/2009/08/19/myl-mylan-drug-gets-tentative-ok/12726</link>
		<comments>http://www.stockbloghub.com/2009/08/19/myl-mylan-drug-gets-tentative-ok/12726#comments</comments>
		<pubDate>Wed, 19 Aug 2009 21:42:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Incorporated]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=12726</guid>
		<description><![CDATA[Yesterday, Mylan Inc. (MYL) announced that its Indian subsidiary, Matrix Laboratories, received tentative approval from the US Food and Drug Administration (FDA) under the President&#8217;s Emergency Plan for AIDS Relief (PEPFAR) for its generic version of a fixed-dose combination of Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate tablets in 600 mg/200mg/300 mg dosage strengths. The decision is in response to an Abbreviated New Drug Application filed by the Indian subsidiary. The tentative approval under PEPFAR is indicative of the fact that the product satisfies all the manufacturing quality, safety and efficacy standards laid down by the agency. The Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate combination is the generic version of Gilead Sciences’ (GILD) Atripla tablets used for the treatment of HIV-1 infection in adults. It combines three anti-AIDS medicines into a single, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/19/myl-mylan-drug-gets-tentative-ok/12726/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

